Controlled Release of Nitric Oxide And Drugs From Functionalized Macromers And Oligomers
申请人:Bezwada Rao S.
公开号:US20120035259A1
公开(公告)日:2012-02-09
The present invention provides NO and, optionally, drug releasing macromers and oligomers wherein the drug molecule and NO releasing moiety are linked an absorbable macromer or oligomeric chain susceptible to hydrolytic degradation and wherein the macromer or oligomer comprises of repeat units derived from safe and biocompatible molecules such as glycolic acid, lactic acid, caprolactone and p-dioxanone. Furthermore, the present invention relates to controlled release of nitric oxide (NO) and/or drug molecule from a NO and drug releasing macromer or oligomer. Moreover, the present invention also relates to medical devices, medical device coatings and therapeutic formulations comprising of nitric oxide and drug releasing macromers and oligomers of the present invention.
The present invention relates to the discovery of a new class of hydrolysable isocyanates, hydrolysable branched polyols and branched absorbable polyesters and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, stents, highly porous foam, reticulated foam, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers can have a controlled hydrolytic degradation profile.
Functionalized drugs and polymers derived therefrom
申请人:Bezwada S. Rao
公开号:US20060172983A1
公开(公告)日:2006-08-03
Compounds selected from:
where DRUG-OH, DRUG-COOH and DRUG-NH
2
are biologically active compounds; each X is independently selected from —CH
2
COO— (glycolic acid moiety), —CH(CH
3
)COO— (lactic acid moiety), —CH
2
CH
2
OCH
2
COO— (dioxanone moiety), —CH
2
CH
2
CH
2
CH
2
CH
2
COO— (caprolactone moiety), —(CH
2
)
y
COO—, where y is 2-4 or 6-24 and —(CH
2
CH
2
O)
z
CH
2
COO—, where z is 2-24; each Y is independently selected from —COCH
2
O— (glycolic ester moiety), —COCH(CH
3
)O— (lactic ester moiety), —COCH
2
OCH
2
CH
2
O— (dioxanone ester moiety), —COCH
2
CH
2
CH
2
CH
2
CH
2
O— (caprolactone ester moiety), —CO(CH
2
)
m
O—, where m is 2-4 or 6-24 and —COCH
2
O(CH
2
CH
2
O)
n
— where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.
FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM
申请人:Bezwada Rao S.
公开号:US20090170927A1
公开(公告)日:2009-07-02
The present invention relates to compounds of formula I, which are functionalized phenolic compounds, and polymers formed from the same.
Ar—[O—(X)
p
—R′]
q
I
Polymers formed from the functionalized phenolics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.
Construction of a meroterpenoid-like compound collection by precursor-assisted biosynthesis
作者:Panlong Ren、Xinyu Miao、Ting Tang、Yueting Wu、Jing Wang、Ying Zeng、Yun Li、Kun Gao、Yan-Long Yang
DOI:10.1039/d0ob01235a
日期:——
generate NP-like compounds offer unique opportunities to access bioactive compounds. Here we present a new approach, precursor-assisted biosynthesis (PAB), for the creation of NP-like compounds by combination of artificial supplementation of common precursors and divergent post-modifications of precursor-deficient fungi. This method was applied to construct a meroterpenoid-like compound collection containing